Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 2 Trial of Daratumumab Dose Schedules in Smoldering Multiple Myeloma
2014-005139-14Phase 2Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of daratumumab in smoldering multiple myeloma (SMM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Complete response rate. Status: unknown.
02
Drugs
daratumumab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2014-005139-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005139-14.